Revolution Medicines develops targeted oncology therapies, including treatments for RAS-addicted cancers.
Daxib (daraxonrasib) uses molecular glue to drug KRAS G12C, previously considered undruggable. Phase 2 shows median overall survival doubled vs chemo (13 vs 7 months) with fewer adverse events. Tango Therapeutics combo further improves survival. First meaningful advance in decades for metastatic pancreatic cancer (3% 5-year survival).